Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine

References

• . Abrams P, Cardozo L, Fall M, ; Standardisation Sub-commmittee of the International Contience Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178
   PubMed Web of Science ®Google Scholar
• . Haylen BT, de Ridder D, Freeman RM, ; International Urogynecological Association; International Contenence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20
   PubMed Web of Science ®Google Scholar
• . Irwin DE, Milsom I, Hunskaar S, . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6): 1306–1315
   PubMed Web of Science ®Google Scholar
• . Nuotio M, Tammela TL, Luukkaala T, Jylha M. Urgency and urge incontinence in an older population: ten-year changes and their association with mortality. Aging Clin Exp Res. 2002;14(5):412–419
   PubMed Web of Science ®Google Scholar
• . Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6( 11 suppl): 574–579
   PubMed Web of Science ®Google Scholar
• . Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53
   PubMed Web of Science ®Google Scholar
• . Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5- hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):481–489
   Web of Science ®Google Scholar
• . Abrams P, Andersson KE, Buccafusco JJ, . Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5): 565–578
   PubMed Web of Science ®Google Scholar
• . Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279–1286
   PubMed Web of Science ®Google Scholar
• . Kay GG, Abou–Donia MB, Messer WS Jr, . Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–2201
   PubMed Web of Science ®Google Scholar
• . Wagg AS, Cardozo L, Chapple C, . Overactive bladder syndrome in older people. BJU Int. 2007;99(3):502–509
   PubMed Web of Science ®Google Scholar
• . DuBeau CE, Kuchel GA, Johnson T 2nd, Palmer MH, Wagg A; Fourth International consultation on Incontenence. Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. Neurourol Urodyn. 2010;29(1):165–178
   PubMed Web of Science ®Google Scholar
• . Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc. 2008;56(12):2203–2210
   PubMed Web of Science ®Google Scholar
• . Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J Gerontol A Biol Sci Med Sci. 2007;62(1):83–85
   PubMed Web of Science ®Google Scholar
• . Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10(5):751–765
   PubMed Web of Science ®Google Scholar
• . Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62 ( suppl 21):11–14
   PubMed Web of Science ®Google Scholar
• . Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008; 56(5):847–853
   PubMed Web of Science ®Google Scholar
• . Jewart RD, Green J, Lu CJ, Cellar J, Tune LE. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4): 324–328
   PubMed Web of Science ®Google Scholar
• . Nikaido AM, Ellinwood EH Jr, Heatherly DG, Gupta SK. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacolog y (Berl). 1990;100(1):90–97
   PubMed Web of Science ®Google Scholar
• . Chapple C, Van Kerrebroeck P, Tubaro A, . Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212
   PubMed Web of Science ®Google Scholar
• . Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102(1):56–61
   PubMed Web of Science ®Google Scholar
• . Dmochowski RR, Peters KM, Morrow JD, . Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology. 2010;75(1):62–68
   PubMed Web of Science ®Google Scholar
• . Kraus SR, Ruiz–Cerdá JL, Martire D, Wang JT, Wagg AS. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology. 2010;76(6):1350–1357
   PubMed Web of Science ®Google Scholar
• . Wagg A, Khullar V, Marschall–Kehrel D, . Assessment of fesoterodine treatment in older people with overactive bladder: Results of SOFIA, a double-blind, placebo-controlled, pan-European trial. European Urology Supplements. 2011;10:276–277
   Web of Science ®Google Scholar
• . Callegari E, Malhotra B, Bungay PJ, . A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235–246
   PubMed Web of Science ®Google Scholar
• . Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005;183(2):133–143
   PubMed Web of Science ®Google Scholar
• . Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl). 2007;191(4):951–959
   PubMed Web of Science ®Google Scholar
• . Vermeeren A, Jackson JL, Muntjewerff ND, . Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. Psychopharmacology (Berl). 1995;118(1):1–9
   PubMed Web of Science ®Google Scholar
• . Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008;46(11):556–563
   PubMed Web of Science ®Google Scholar
• . Malhotra B, Sachse R, Wood N. Influence of food on the pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2009;47(6): 384–390
   PubMed Web of Science ®Google Scholar
• . Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl). 1984;84(4):452–456
   PubMed Web of Science ®Google Scholar
• . Maruff P, Thomas E, Cysique L, . Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2): 165–178
   PubMed Web of Science ®Google Scholar
• . Callahan CD, Johnstone B. The clinical utility of the Rey Auditory-Verbal Learning Test in medical rehabilitation. J Clin Psychol Med Settings. 1994;1:261–268
   PubMed Web of Science ®Google Scholar
• . Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol. 2006;28(7):1095–1112
   PubMed Web of Science ®Google Scholar
• . Falleti MG, Maruff P, Collie A, Darby DG, McStephen M. Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res. 2003;12(4):265–274
   PubMed Web of Science ®Google Scholar
• . Fredrickson A, Snyder PJ, Cromer J, Thomas E, Lewis M, Maruff P. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum Psychopharmacol. 2008;23(5):425–436
   PubMed Web of Science ®Google Scholar
• . Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27(1):127–138
   PubMed Web of Science ®Google Scholar
• . Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9(10):1787–1796
   PubMed Web of Science ®Google Scholar
• . Kay G, Crook T, Rekeda L, . Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–326
   PubMed Web of Science ®Google Scholar
• . Katz IR, Sands LP, Bilker W, . Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46(1):8–13
   PubMed Web of Science ®Google Scholar
• . Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutyinin chloride ER on recent memory in older subjects Presented at: International Continence Society; November 26 to December 1, 2006; Christchurch, New Zealand
   Google Scholar
• . Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96(7):1055–1062
   PubMed Web of Science ®Google Scholar
• . Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792–1800
   PubMed Web of Science ®Google Scholar
• . Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615–626
   PubMed Web of Science ®Google Scholar
• . Staskin D, Kay G, Tannenbaum C, . Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–1300
   PubMed Web of Science ®Google Scholar
• . US Census Bureau. U.S. Summary: 2000, Census 2000 Profile. U.S. Department of Commerce. Available at: http://www.census.gov/prod/2002pubs/c2kprof00-us.pdf. Accessed June 9, 2008
   Google Scholar